Table 1.
Tumor ID | S/A | Diagnosis | Methst | RelmRNA Expr | Tumor ID | S/A | Diagnosis | Methst | RelmRNA Expr |
1074D | M/44 | AII | m | nd | 3728 | M/74 | GBM | m | nd |
2307 | M/35 | AII | m | nd | 4006 | M/38 | GBM | m | 0.21 (± 0.05) |
2154 | M/30 | AII | m | 0.33 (± 0.07) | 4032 | M/35 | GBM | m | 0 |
2246 | F/11 | AII | m | 0.11 (± 0.01) | 4416 | M/61 | GBM | m | 1.1 (± 0.1) |
2316 | M/35 | AII | m | 0 | 4594 | F/52 | GBM | m | 9.7 (± 1.85) |
3022 R | F/29 | AII | m | 2.44 (± 0.34) | 4714 | F/39 | GBM | m | 0 |
3294 R | F/34 | AII | m | 0.8 (± 0.03) | 4732 | F/61 | GBM | m | 0.1 (± 0.01) |
3632 | M/55 | AII | m | 27.67 (± 4.51) | 4804 | M/57 | GBM | m | 0.21 (± 0.08) |
4948 | M/46 | AII | m | nd | 4936 | F/37 | GBM | m | nd |
5232 R | M/36 | AII | m | 0.88 (± 0.05) | 4944 | F/59 | GBM | m | 0.2 (± 0.04) |
7282 | M/29 | AII | m | 1.07 (± 0.39) | 4962 | F/70 | GBM | m | 0.07 (± 0.01) |
7342 | M/40 | AII | m | 0 | 5162 | F/78 | GBM | m | 8.16 (± 0.57) |
9306 | F/55 | AII | m | 0.18 (± 0.15) | 6236 | M/69 | GBM | m | 13.8 (± 1.14) |
9421 | F/37 | AII | m | 0.82 (± 0.2) | 6840 | M/54 | GBM | m | nd |
9640 | M/32 | AII | m | 0.2 (± 0.02) | 10120 R | M/40 | GBM | m | 98.47 (± 29.5) |
11092 | M/35 | AII | m | 0.52 (± 0.03) | 11418 | F/68 | GBM | m | 0.4 (± 0.01) |
11240 | M/25 | AII | m | 0.29 (± 0.05) | 11571 | F/70 | GBM | m | 16.74 (± 3.8) |
12020 R | F/21 | AII | m | 0.93 (± 0.26) | 11666 | M/42 | GBM | m | 0.05 (± 0.01) |
9004 R | F/32 | AII | nm | 26.7 (± 2.19) | 4530 | F/66 | GBM | nm | 0.08 (± 0.01) |
7564 | M/38 | AII | nm | 18.5 (± 2.49) | 4548 | F/60 | GBM | nm | 0 |
2392 R | F/41 | AIII | m | nd | 4400 | M/49 | GBM | nd | 0 |
2754 | F/50 | AIII | m | 1.03 (± 0.04) | 11637 | F/52 | GBM | nm | 3.1 (± 0.2) |
2814 | M/16 | AIII | m | 1.44 (± 0.01) | 308D | GBMcl | m | nd | |
7006 | M/42 | AIII | m | nd | A1207D | GBMcl | m | nd | |
7020 | M/32 | AIII | m | nd | LN229D | GBMcl | m | nd | |
9846 | F/50 | AIII | m | 0.05 (± 0.02) | U178MG | GBMcl | m | 0.13 (± 0.01) | |
10048 | M/49 | AIII | m | 0.18 (± 0.04) | U178MG+ | GBMcl | 10.4 (± 1.96) | ||
10760 | F/30 | AIII | m | 1.14 (± 0.12) | U87MG | GBMcl | m | 0.2 (± 0.01) | |
11060 | F/32 | AIII | m | 0.09 (± 0.01) | U87MG+ | GBMcl | 25.26 (± 7.16) | ||
11226 | F/32 | AIII | m | 0.18 (± 0.02) | LN428 | GBMcl | m | 0 | |
12442 | F/28 | AIII | m | nd | LN428 ++ | GBMcl | 4.13 (± 0.28) | ||
12490 | F/51 | AIII | m | 0.57 (± 0.15) | A172 | GBMcl | m | 0 | |
2446 | F/62 | AIII | nm | 14.6 (± 1.02) | A172 + | GBMcl | 2.6 (± 0.24) | ||
10414 | F/38 | AIII | nm | 5.62 (± 0.32) | U373MG | GBMcl | m | 0 | |
537D R | M/49 | GBM | m | nd | U373MG+ | GBMcl | 11.36 (± 2.71) | ||
1150D R | M/62 | GBM | m | nd | NB | WM,GM | 7.8 (± 1.49) |
M, male; F, female; R, recurrent; AII, diffuse astrocytoma of WHO grade II; AIII, anaplastic astrocytoma of WHO grade III; GBM, glioblastoma of WHO grade IV; GBMcl, glioma cell line; S/A, sex/age; m, methylated; nm, not methylated; (+) 0.5 µM 5-aza-2′-deoxycytidine; (++) 1 µM 5-aza-2′-deoxycytidine; nd, not determined; NB, pool of normal brain (white and grey matter) samples; WM, white matter; GM, grey matter (cortex); Methst, methylation status; RelmRNA Expr, relative transcription levels and standard error of PCDH-γ-A11 expression are indicated.